New survey tracks Real-World use of entyvio for Crohn's disease
NCT ID NCT04002180
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is a survey of 335 people with moderate to severe Crohn's disease who are taking Entyvio (vedolizumab) as part of their regular care. The goal is to see how safe and effective the drug is over the long term in everyday medical practice. Researchers will track side effects and changes in disease activity. This is not a cure, but aims to help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Takeda Selected Site
Tokyo, Japan